AF
VRDN icon

Allworth Financial’s Viridian Therapeutics VRDN Stock Holding History

Allworth Financial’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5K Buy
625
+591
+1,738% +$9.52K ﹤0.01% 3619
2026
Q1 		$666 Buy
34
+1
+3% +$30 ﹤0.01% 4673
2025
Q4 		$1.03K Hold
33
– – ﹤0.01% 4346
2025
Q3 		$713 Hold
33
– – ﹤0.01% 4351
2025
Q2 		$462 Hold
33
– – ﹤0.01% 4157
2025
Q1 		$448 Buy
+33
New +$562 ﹤0.01% 3711

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Allworth Financial's VRDN Position: Q2 2026 in Review

Allworth Financial increased its Viridian Therapeutics (VRDN) stake by 1,738% in Q2 2026, buying an estimated $9.52K and bringing the position to 625 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3619.

Allworth Financial first reported a position in VRDN in Q1 2025 and has held it in 6 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Allworth Financial held 625 shares of Viridian Therapeutics worth $11.5K as of Q2 2026.
  • Allworth Financial bought 591 Viridian Therapeutics shares in Q2 2026, an estimated $9.52K.
  • Viridian Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3619 holding.
  • Allworth Financial first reported a position in Viridian Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.